<DOC>
	<DOCNO>NCT00291785</DOCNO>
	<brief_summary>CT-2106 , camptothecin ( CPT ) conjugate , new generation topoisomerase I inhibitor design deliver high , effective chemotherapy tumor tissue less toxicity normal tissue . The objective study determine dose limit toxicity , safety profile antitumor activity CT-2016 combination 5-FU folic acid treatment colorectal cancer .</brief_summary>
	<brief_title>Phase I/II CT 2106 5-FU/FA Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histologically prove metastatic colorectal adenocarcinoma , fail one prior treatment contain oxaliplatin plus 5FU/FA At least one measurable lesion accord RECIST criterion Phase I II ECOG performance status 0 1 Adequate hematologic , renal hepatic function Wash period least 4 week surgery , 4 week radiotherapy Past concurrent history neoplasm colorectal adenocarcinoma , except curatively treat non melanoma skin cancer situ carcinoma cervix . Pregnant lactating patient Prior treatment camptothecins Presence history CNS metastasis carcinomatous leptomeningitis Current active infection per investigator assessment Unresolved bowel obstruction partial obstruction , uncontrolled Crohn 's disease ulcerative colitis Current history chronic diarrhea great equal grade 1 ( CTCAE version 3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>camptothecin</keyword>
</DOC>